CoChat
Sign Up
Cited by 13

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration: A PRISMA-compliant network meta-analysis of randomized controlled trials

Wei, Yanli, Liao, Hongxia, Ye, Jian·2018·Medicine
DOI 10.1097/md.0000000000010422PMC PMC6393096
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/md.0000000000010422

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 35

  1. Wong, 2014, Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis, Lancet Glob Health, 2, e106, 10.1016/S2214-109X(13)70145-1 · DOI
  2. Lim, 2012, Age-related macular degeneration, Lancet, 379, 1728, 10.1016/S0140-6736(12)60282-7 · DOI
  3. Flaxman, 2017, Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis, Lancet Glob Health, 5, e1221, 10.1016/S2214-109X(17)30393-5 · DOI · Paper page
  4. Sacconi, 2017, A review of current and future management of geographic atrophy, Ophthalmol Ther, 6, 69, 10.1007/s40123-017-0086-6 · DOI
  5. Holz, 2014, Geographic atrophy: clinical features and potential therapeutic approaches, Ophthalmology, 121, 1079, 10.1016/j.ophtha.2013.11.023 · DOI
  6. Li, 2017, Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development, Expert Opin Investig Drugs, 26, 1103, 10.1080/13543784.2017.1369042 · DOI
  7. Sadda, 2016, Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration, Retina, 36, 1806, 10.1097/IAE.0000000000001283 · DOI
  8. Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann Intern Med, 162, 777, 10.7326/M14-2385 · DOI · Paper page
  9. Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 · DOI · Paper page
  10. Ades, 2005, The interpretation of random-effects meta-analysis in decision models, Med Decis Making, 25, 646, 10.1177/0272989X05282643 · DOI
  11. Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, J Clin Epidemiol, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
  12. Li, 2015, Effects of fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis, PLoS One, 10, e0145066, 10.1371/journal.pone.0145066 · DOI
  13. Yaspan, 2017, Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration, Sci Transl Med, 9, eaaf1443, 10.1126/scitranslmed.aaf1443 · DOI
  14. Shiragami, 2017, Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration, Medicine (Baltimore, 96, e6422, 10.1097/MD.0000000000006422 · DOI
  15. Tao, 2016, alpha-lipoic acid treatment improves Vision-Related Quality of Life in patients with dry age-related macular degeneration, Tohoku J Exp Med, 240, 209, 10.1620/tjem.240.209 · DOI
  16. Rencova, 2015, Preservation of the photoreceptor inner/outer segment junction in dry age-related macular degeneration treated by rheohemapheresis, J Ophthalmol, 2015, 359747, 10.1155/2015/359747 · DOI
  17. Jaffe, 2015, Randomized trial to evaluate tandospirone in geographic atrophy secondary to age-related macular degeneration: the GATE study, Am J Ophthalmol, 160, 1226, 10.1016/j.ajo.2015.08.024 · DOI
  18. Dugel, 2015, Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration, Retina, 35, 1173, 10.1097/IAE.0000000000000606 · DOI
  19. Yehoshua, 2014, Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study, Ophthalmology, 121, 693, 10.1016/j.ophtha.2013.09.044 · DOI · Paper page
  20. Petrou, 2014, Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial, Invest Ophthalmol Vis Sci, 56, 330, 10.1167/iovs.14-15877 · DOI
  21. Wong, 2013, Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial, Invest Ophthalmol Vis Sci, 54, 2941, 10.1167/iovs.13-11650 · DOI
  22. Mata, 2013, Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration, Retina, 33, 498, 10.1097/IAE.0b013e318265801d · DOI · Paper page
  23. Dawczynski, 2013, Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study, Graefes Arch Clin Exp Ophthalmol, 251, 2711, 10.1007/s00417-013-2376-6 · DOI
  24. Blaha, 2013, Rheohaemapheresis in the treatment of nonvascular age-related macular degeneration, Atheroscler Suppl, 14, 179, 10.1016/j.atherosclerosissup.2012.10.023 · DOI
  25. Augustin, 2013, Alprostadil infusion in patients with dry age related macular degeneration: a randomized controlled clinical trial, Expert Opin Investig Drugs, 22, 803, 10.1517/13543784.2013.794782 · DOI
  26. Borrelli, 2012, Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study, Int J Ophthalmol, 5, 708
  27. Zhang, 2011, Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration, Proc Natl Acad Sci U S A, 108, 6241, 10.1073/pnas.1018987108 · DOI
  28. Rencova, 2011, Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form, Acta Ophthalmol, 89, 463, 10.1111/j.1755-3768.2009.01710.x · DOI
  29. Koss, 2009, Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART, Graefes Arch Clin Exp Ophthalmol, 247, 1297, 10.1007/s00417-009-1113-7 · DOI
  30. Newsome, 2008, A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration, Curr Eye Res, 33, 591, 10.1080/02713680802178437 · DOI
  31. Pulido, 2006, Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results, Trans Am Ophthalmol Soc, 104, 221
  32. Richer, 2004, Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial), Optometry, 75, 216, 10.1016/S1529-1839(04)70049-4 · DOI
  33. Rodanant, 2002, Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration, Am J Ophthalmol, 134, 577, 10.1016/S0002-9394(02)01691-4 · DOI
  34. Richer, 1996, Multicenter ophthalmic and nutritional age-related macular degeneration study–part 2: antioxidant intervention and conclusions, J Am Optom Assoc, 67, 30
  35. Pierson, 2016, Health-related quality of life in patients with moderate to advanced dry age-related macular degeneration: results from a phase 1/2a clinical trial of Cnto 2476, Value Health, 19, A127, 10.1016/j.jval.2016.03.1861 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wei, Y., Liao, H., & Ye, J.
Venue
Medicine
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2018-05
Volume
97
Issue
21
Pages
e10422
ISSN
0025-7974
DOI
10.1097/md.0000000000010422
PMC
PMC6393096
Cited by
13
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review